Evolving role of bone biomarkers in castration-resistant prostate cancer

Neoplasia

Volumn 12, Issue 9, 2010, Pages 685-696

  Brown, Janet E ^a   Sim, Sheryl ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTIANDROGEN; ATRASENTAN; BIOLOGICAL MARKER; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; DASATINIB; DENOSUMAB; DEOXYPYRIDINOLINE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; KALLIKREIN; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OSTEOPROTEGERIN; PHOSPHORUS 32; PLACEBO; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE; RADIOISOTOPE; RADIUM 223; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COLORECTAL CANCER; COLORIMETRY; DIAGNOSTIC VALUE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INHIBITION KINETICS; JAW OSTEONECROSIS; MALE; MEDICAL DECISION MAKING; MORTALITY; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RADIOIMMUNOASSAY; RISK ASSESSMENT; SINGLE DRUG DOSE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 77956832136     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10610     Document Type: Article

References (121)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, and Boyle P (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18, 581-592.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
3. Sternberg CN (2008). Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 19, vii91-vii95.
4. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26, 1148-1159.
5. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, and Mihatsch MJ (2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31, 578-583.
6. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, and Blute ML (2002). Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 95, 1028-1036.
7. Rajpar S, Massard C, Laplanche A, Tournay E, Gross-Goupil M, Loriot Y, Di PM, Bossi A, Escudier B, Chauchereau A, et al. (2010). Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol, E-pub ahead of print.
8. Carlin BI and Andriole GL (2000). The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88, 2989-2994.
9. Kingsley LA, Fournier PG, Chirgwin JM, and Guise TA (2007).Molecular biology of bone metastasis. Mol Cancer Ther 6, 2609-2617.
10. Roodman GD (2004). Mechanisms of bone metastasis. N Engl J Med 350, 1655-1664.
11. Fohr B, Dunstan CR, and Seibel MJ (2003). Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88, 5059-5075.
12. Coleman RE (1997). Skeletal complications of malignancy. Cancer 80, 1588-1594.
13. Seibel MJ (2005). Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2, 504-517.
14. Coleman RE (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27, 165-176.
15. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, and Schulman KA (2005). The significance of skeletal-related events for the healthrelated quality of life of patients with metastatic prostate cancer. Ann Oncol 16, 579-584.
16. Saad F, Lipton A, Cook R, Chen YM, Smith M, and Coleman R (2007). Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110, 1860-1867.
17. Saad F, Chen YM, Gleason DM, and Chin J (2007). Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 5, 390-396.
18. Major PP, Cook RJ, Chen BL, and Zheng M (2005). Survival-adjusted multipleevent analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2, 234-240.
19. Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, and Scher HI (2007). American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 25, 5313-5318.
20. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351, 1513-1520.
21. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351, 1502-1512.
22. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, and Frith JC (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88, 2961-2978.
23. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, and Chen B (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94, 1458-1468.
24. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, and Zheng M (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96, 879-882.
25. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, and Duh MS (2007). The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 109, 1090-1096.
26. Ortega C, Faggiuolo R, Vormola R, Montemurro F, Nanni D, Goia F, and Aglietta M (2006). Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol 45, 216-217.
27. Kyrgidis A and Toulis KA (2010). Denosumab-related osteonecrosis of the jaws. Osteoporos Int, E-pub ahead of print.
28. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, et al. (2007). Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8, 587-594.
29. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di PM, Escudier B, Theodore C, Loriot Y, et al. (2009). Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castrationresistant prostate cancer. J Clin Oncol 27, 2429-2435.
30. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, et al. (2009). Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27, 2436-2442.
31. Smith DC, Dunn RL, Strawderman MS, and Pienta KJ (1998). Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormonerefractory prostate cancer. J Clin Oncol 16, 1835-1843.
32. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, and Eisenberger M (2007). Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25, 3965-3970.
33. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, et al. (2009). Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group trials 9346 (intergroup study 0162) and 9916. J Clin Oncol 27, 2450-2456.
34. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. (2009). Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360, 1320-1328.
35. van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, et al. (2005). Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 48, 1031-1041.
36. Ramiah V, George DJ, and Armstrong AJ (2008). Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 18, 303-308.
37. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, et al. (2008). A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14, 209-214.
38. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, and Smith MR (2009). Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20, 913-920.
39. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, and Major P (2008). Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34, 629-639.
40. Melkko J, Niemi S, Risteli L, and Risteli J (1990). Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36, 1328-1332.
41. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, and Risteli J (1996). Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42, 947-954.
42. Orum O, Hansen M, Jensen CH, Sorensen HA, Jensen LB, Horslev-Petersen K, and Teisner B (1996). Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 19, 157-163.
43. Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, and Kung VT (1995). Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41, 1560-1566.
44. Woitge HW, Seibel MJ, and Ziegler R (1996). Comparison of total and bonespecific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem 42, 1796-1804.
45. Lee AJ, Hodges S, and Eastell R (2000). Measurement of osteocalcin. Ann Clin Biochem 37, 432-446.
46. Arbault P, Grimaux M, Pradet V, Preaudat C, Seguin P, and Delmas PD (1995). Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Bone 16, 461-467.
47. Vesper HW, Audain C, Woolfitt A, Ospina M, Barr J, Robins SP, and Myers GL (2003). High-performance liquid chromatography method to analyze free and total urinary pyridinoline and deoxypyridinoline. Anal Biochem 318, 204-211.
48. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, and Seibel MJ (1994). Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9, 1643-1649.
49. Bonde M, Qvist P, Fledelius C, Riis BJ, and Christiansen C (1994). Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40, 2022-2025.
50. Bonde M, Fledelius C, Qvist P, and Christiansen C (1996). Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem 42, 1639-1644.
51. Gertz BJ, Clemens JD, Holland SD, Yuan W, and Greenspan S (1998). Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63, 102-106.
52. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, and Eyre DR (1992). A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J BoneMiner Res 7, 1251-1258.
53. Risteli J, Elomaa I, Niemi S, Novamo A, and Risteli L (1993). Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39, 635-640.
54. Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R, and Armbruster FP (1997). Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem 43, 2076-2082.
55. Fedarko NS, Jain A, Karadag A, Van Eman MR, and Fisher LW (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7, 4060-4066.
56. Chen D, Sarikaya NA, Gunn H, Martin SW, and Young JD (2001). ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clin Chem 47, 747-749.
57. Kraenzlin ME, Lau KH, Liang L, Freeman TK, Singer FR, Stepan J, and Baylink DJ (1990). Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 71, 442-451.
58. Lau KH, Onishi T, Wergedal JE, Singer FR, and Baylink DJ (1987). Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 33, 458-462.
59. Jukkola A, Tahtela R, Tholix E, Vuorinen K, Blanco G, Risteli L, and Risteli J (1997). Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 57, 5517-5520.
60. Koizumi M, Yonese J, Fukui I, and Ogata E (2001). The serum level of the aminoterminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87, 348-351.
61. Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Reginster JY, and Gangji V (2009). Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63, 19-26.
62. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, and Rabbani SA (2006). Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107, 289-298.
63. Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, and Terpos E (2007). Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46, 221-229.
64. Seibel MJ (2000).Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 11, S18-S29.
65. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, and Delaisse JM (2003). The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J BoneMiner Res 18, 859-867.
66. Bianco P, Fisher LW, Young MF, Termine JD, and Robey PG (1991). Expression of bone sialoprotein (BSP) in developing human tissues. CalcifTissue Int 49, 421-426.
67. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, and Castronovo V (1998). Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90, 1000-1008.
68. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, and Vaananen HK (2001). Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47, 597-600.
69. Garnero P (2001). Markers of bone turnover in prostate cancer. Cancer Treat Rev 27, 187-192.
70. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, and Delmas PD (2000). Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82, 858-864.
71. Klepzig M, Jonas D, and Oremek GM (2009). Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res 29, 671-673.
72. Koopmans N, de Jong IJ, Breeuwsma AJ, and van der Veer E (2007). Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178, 849-853.
73. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, and Tanko LB (2006). The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15, 32-38.
74. Jung K, Lein M, Stephan C, Von HK, Semjonow A, Sinha P, Loening SA, and Schnorr D (2004). Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111, 783-791.
75. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, and Coleman RE (2005). Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97, 59-69.
76. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, et al. (2005). Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23, 4925-4935.
77. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, and Smith MR (2006).Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12, 3361-3367.
78. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, and Iversen P (2006). Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66, 503-513.
79. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, and Christensen IJ (2007). Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 13, 3244-3249.
80. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, and Coleman RE (2008). Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113, 193-201.
81. Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, and Raptis SA (2005). Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 25, 1457-1463.
82. Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, et al. (2007). Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52, 1381-1387.
83. Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, and Jung K (2009). Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 69, 624-632.
84. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, et al. (2003). Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebocontrolled trial. J Clin Oncol 21, 679-689.
85. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, and Carducci MA (2003). Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169, 1143-1149.
86. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, and Nelson JB (2007). A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormonerefractory prostate cancer. Cancer 110, 1959-1966.
87. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, and Smith MR (2006). Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 107, 530-535.
88. Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, et al. (2008). A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 14, 6270-6276.
89. Schelman WR, Liu G, Wilding G, Morris T, Phung D, and Dreicer R (2009). A phase I study of zibotentan (ZD4054) in patients with metastatic, castrateresistant prostate cancer. Invest New Drugs, E-pub ahead of print.
90. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng S, et al. (2009). Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15, 7421-7428.
91. Yu EY, Massard C, Gross M, Wilding G, Posadas E, Culine S, Carducci M, Trudel G, Paliwal P, and Sternberg C (2009). A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CA180085). J Clin Oncol 27, 270s. Abstract 5147.
92. Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick G, Trudel GC, Paliwal P, and Logothetis CJ (2009). Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of study CA180-086. Eur J Cancer 7, 415S. Abstract 7028.
93. Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD, and Eastell R (2010). Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. J Bone Miner Res 25, 463-471.
94. Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, and Gandara DR (2009). A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20, 179-184.
95. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, and Fizazi K (2010). Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res 25, 440-446.
96. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, and Jun S (2009). Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27, 1564-1571.
97. Fizazi K, Bosserman L, Gao G, Skacel T, andMarkus R (2009). Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 182, 509-515.
98. Amgen Press Release (2010). Denosumab demonstrated superiority over zometa in pivotal phase 3 head-to-head trial in prostate cancer patients with bone metastases. Available at http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1385163. Accessed March 2010.
99. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, and Dibb NJ (2009). Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 23, 590-594.
100. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. (2004). Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47, 6658-6661.
101. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, and Jove R (2005). Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65, 9185-9189.
102. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, and Gallick GE (2008). Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68, 3323-3333.
103. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik TL, Hughes TP, and Zannettino AC (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 23, 994-997.
104. de Vries TJ, Mullender MG, van Duin MA, Semeins CM, James N, Green TP, Everts V, and Klein-Nulend J (2009). The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 7, 476-488.
105. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, and Evans CP (2009). Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 69, 151-160.
106. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, and Guise TA (2003). A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100, 10954-10959.
107. Guise TA, Yin JJ, and Mohammad KS (2003). Role of endothelin-1 in osteoblastic bone metastases. Cancer 97, 779-784.
108. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, and Dawson NA (2009). Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebocontrolled, randomised, phase 2 trial. Eur Urol 55, 1112-1123.
109. Watts NB (1999). Clinical utility of biochemical markers of bone remodeling. Clin Chem 45, 1359-1368.
110. Conrads TP, Hood BL, Petricoin EF III, Liotta LA, and Veenstra TD (2005). Cancer proteomics: many technologies, one goal. Expert Rev Proteomics 2, 693-703.
111. Tang HY, li-Khan N, Echan LA, Levenkova N, Rux JJ, and Speicher DW (2005). A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 5, 3329-3342.
112. Bhattacharyya S, Byrum S, Siegel ER, and Suva LJ (2007). Proteomic analysis of bone cancer: a review of current and future developments. Expert Rev Proteomics 4, 371-378.
113. Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, and Suva LJ (2006). Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark 2, 249-258.
114. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, and Sadar MD (2005). Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51, 695-707.
115. Bhattacharyya S, Epstein J, and Suva LJ (2006). Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. Dis Markers 22, 245-255.
116. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, et al. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13, 7053-7058.
117. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Vaananen RM, Pettersson K, Chun FK, et al. (2009). Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 55, 765-773.
118. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, and Raghavan D (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castrationresistant prostate cancer. Clin Cancer Res 14, 6302-6309.
119. Scher HI, Jia X, deBono JS, Fleisher M, Pienta KJ, Raghavan D, and Heller G(2009). Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10, 233-239.
120. Armstrong AJ and Febbo PG (2009). Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 14, 816-827.
121. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, et al. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12, 6213s-6216s.